Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02102971 · ClinicalTrials.gov registry record

Observational Study of Biomarker During Liver Surgery

A clinical trial, sponsored by University of Florida.

Terminated
Registry status
41
Enrollment target

NCT02102971: Clinical Trial study, sponsored by University of Florida.

NCT02102971 is a clinical trial that was terminated before completion, run by University of Florida. The registered enrollment target is 41 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02102971 was terminated before completion, sponsored by University of Florida.

TERMINATED
Registry status
41 participants
Enrollment target

Study Summary

The investigators would like to study whether Sirtuin 1 (SIRT1) plays a cytoprotective role in liver ischemia/reperfusion, and ultimately to develop therapeutic strategies to improve hepatic function of patients with liver diseases.

Interventions

  • PROCEDURE Hepatocellular carcinoma

Trial Details

FieldValue
Enrollment Target 41 participants
Start Date 2014-10
Est. Completion 2019-06-06
University of Florida

1,106 total trials

Why NCT02102971 stopped before completion

NCT02102971 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 41 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which Hepatocellular carcinoma is the first listed.

NCT02102971 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02102971 about?

NCT02102971 is a clinical study titled "Observational Study of Biomarker During Liver Surgery". The investigators would like to study whether Sirtuin 1 (SIRT1) plays a cytoprotective role in liver ischemia/reperfusion, and ultimately to develop therapeutic strategies to improve hepatic function of patients with liver diseases.

What is the current status of trial NCT02102971?

This trial is currently terminated. The enrollment target is 41 participants. The study started on 2014-10. Estimated completion is 2019-06-06.

What interventions are being tested in trial NCT02102971?

The interventions under investigation include: Hepatocellular carcinoma (PROCEDURE).

Who is sponsoring clinical trial NCT02102971?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03449238 · 41 participants · Phase 1

    Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

  • NCT03900793 · 41 participants · Phase 1

    Losartan + Sunitinib in Treatment of Osteosarcoma

  • NCT04082520 · 41 participants · Phase 2

    Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

  • NCT04220190 · 41 participants · Phase 2

    RAPA-501 Therapy for ALS

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02102971, the US trial registry maintained by the National Library of Medicine. NCT02102971 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.